

## Research Article

## “Comparison of Silodosin (8 Mg) Versus Tamsulosin (0.4 Mg), Both in Terms of the Stone Expulsion Rate and the Time to Stone Expulsion”

Khan Nazrul Islam<sup>1\*</sup>, S.A. Anwarul Quadir<sup>2</sup>, Md. Naushad Alam<sup>3</sup>, Md. Shawkat Alam<sup>4</sup>, Bivash Boran<sup>5</sup><sup>1</sup>Assistant Professor, Dept. of Urology, National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, Bangladesh<sup>2</sup>Assistant Professor, Dept. of Urology, National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, Bangladesh<sup>3</sup>Assistant Professor, Dept. of Urology, National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, Bangladesh<sup>4</sup>Professor, Dept. of Urology, National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, Bangladesh<sup>5</sup>Assistant Professor, Dept. of Urology, Dhaka Medical College Hospital, Dhaka, Bangladesh**Article History**

Received: 09.02.2021

Accepted: 20.02.2021

Published: 27.02.2021

**Journal homepage:**<https://www.easpublisher.com>**Quick Response Code**

**Abstract: Background:** Ureteral stones account for 22% of all urinary tract stones with 68% of them being located in the distal ureter. Conservative management strategies such as observation or medical expulsive therapy (MET) using pharmacological agents to facilitate spontaneous passage of ureteral stones have gained popularity in the management of ureteral stones during the recent years. **Objectives:** To compare the efficacy of silodosin (8 mg) versus tamsulosin (0.4mg), both in terms of the stone expulsion rate and the time to stone expulsion. **Patients and Methods:** A prospective and randomized controlled study was conducted in the department of Urology, National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, Bangladesh. Starting from October 2018, till September 2019; a total of 96 patients (M=56; F=40) who were between age group of 18–50 years, who had unilateral, non-impacted, uncomplicated middle or lower and lower or middle ureteral stones which were  $\leq 1\text{cm}$  and  $\leq 0.9\text{cm}$  were enrolled in a prospective study and they were randomized into two groups. Group 1 received tamsulosin (0.4mg), and group 2 received silodosin (8mg) for a maximum period of 4 weeks. The patients were followed up weekly or biweekly with imaging studies. **Results:** Four patients in Group A and six patients in Group B were lost to follow-up, with 86 patients remaining for per-protocol analyses. No significant differences were found between the groups with respect to age, stone size, or stone location. Spontaneous stone expulsion was observed in 26 of 44 patients (59%) in Group A and in 34 of 42 patients (80%) in Group B ( $P=0.027$ ). The primary endpoint was the stone expulsion rate, and the secondary endpoint was the time to stone expulsion. Stone expulsion rate was observed in 59% of patients in group 1 and in 80% of patients in group 2, which was statistically significant. There was also significant difference between groups with regard to mean time to stone expulsion. **Conclusion:** Silodosin was more effective than tamsulosin with regard to stone expulsion rate and with a less mean time to stone expulsion.

**Keywords:** Ureteric Stone, Silodosin, Tamsulosin, Medical Expulsive Therapy.

**Copyright © 2021 The Author(s):** This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

## INTRODUCTION

Ureteral stones account for 22 % of all urinary tract stones with 68 % of them being located in the distal ureter. Conservative management strategies such as observation or medical expulsive therapy (MET) using pharmacological agents to facilitate spontaneous passage of ureteral stones have gained popularity in the management of ureteral stones during the recent years. Urinary stones have afflicted humankind since antiquity, with the earliest literary quotations to stone disease, describing symptoms and prescribing treatments to dissolve the stone, are observed within the medical texts of Asutu in Mesopotamia between 3200 and 1200 BC [1]. Evidence on the association of stone size with spontaneous stone passage rates is scarce. 95 % of stones up to 4 mm are estimated to pass within 40

days. Conservative management strategies such as observation or medical expulsive therapy (MET) using pharmacological agents to facilitate spontaneous passage of ureteral stones have gained popularity in the management of ureteral stones during the recent years. Evidence on the association of stone size with spontaneous stone passage rates is scarce. Ureteral stones occupy an important place in daily urological practice, that causing an acute attack of ureteral colic by obstructing the ureter [2]. Of all urinary tract stones, ureteral stones are 20% and 70% of these stones are located in the distal portion of the ureter [3]. There has been a paradigm shift in the management of the ureteral calculi in the past decade, with the introduction of minimally invasive techniques and newer drugs [4]. An excellent results with recent studies have reported with the medical expulsion therapy for the distal ureteral

calculi, with alpha 1 blockers [5]. Silodosin has been also proposed for MET instead of tamsulosin but studies comparing these substances for MET are scarce. In this systematic review and analysis we aim to review current literature and compare the success rates of silodosin to tamsulosin for MET of ureteral stones.

#### Treatment Methods of Ureterolithiasis

1. Observation (also termed “watchful waiting” and “expectant management”).
2. Medical expulsive therapy (MET).
3. Shock wave lithotripsy (SWL).
4. Ureteroscopy (URS).
5. Percutaneous Antegradeureteroscopy (PAURS).
6. Laparoscopic surgery.
7. Open surgery [6, 7].

#### Indications for Active Removal of Ureteral Stones

1. Stones with low likelihood of spontaneous passage {for example: stones associated with ureteric stricture, stones <1 cm} [6].
2. Persistent pain despite adequate analgesic medication [7].
3. Persistent obstruction [7].
4. Renal insufficiency (bilateral obstruction, or single kidney, renal failure) [6].
5. The patient’s employment (machinery, pilots) [4].

#### Medical Expulsive Therapy (MET)

Patients who have newly diagnosed ureteric stones who have no indication for active removal of ureteric stones (listed above) and of less than 10 mm in size, may be offered appropriate medical therapy to facilitate stone passage during observation (Medical Expulsive Therapy) i.e. {the administration of drugs to facilitate stone passage} [6]. There is growing evidence that (MET) can be efficacious [6]. And the use of (MET) has become an accepted practice [2]. Meta-analyses have shown that patients with ureteral stones manage with nifedipine or  $\alpha$ -blockers are more likely to pass stones with less episodes of ureteric colic than those not taking such therapy [5, 8]. Tamsulosin, An adrenergic antagonist ( $\alpha_{1A}$ ,  $\alpha_{1D}$ ) is effective medical agents and the most popular one, which is used for the expulsive therapy (probably because of its lack of a need for dose titration upon initiation of treatment and the excellent tolerability) [6]. Silodosin, a recently introduced selective  $\alpha_1$  adrenoceptor antagonist, has shown promising results with fewer side effects and a better efficacy [9].

#### Factors Affecting Medical Expulsion Therapy

1. Stone size: MET is less likely to increase the stone-free rate, due to the high likelihood of spontaneous passage of stones up to ~5 mm, [10-13].
2. Stone location: The vast majority of trials have investigated distal ureteral stones [4]. One randomized clinically controlled trial (RCT) has assessed the effect of tamsulosin on spontaneous passage of proximal ureteral calculi 5-10 mm [14]. The main effect was to encourage stone migration to a more distal part of the ureter [14].
3. Medical expulsive therapy after extracorporeal shock wave lithotripsy (SWL): Clinical studies and several meta-analyses have shown that MET after SWL for ureteral or renal stones can expedite expulsion and increase stone free rate and reduce analgesic requirements [15-17].
4. Medical expulsive therapy after ureteroscopy: Medical expulsive therapy following holmium: YAG laser lithotripsy increases stone free rates and reduce colic episodes [18].
5. Duration of medical expulsive therapy treatment: Most studies have had duration of 30 days or 1 month [19].

Alpha 1 adrenoceptors (ARs) are a class of proteins belonging to the G protein-coupled receptor family [20]. Molecular heterogeneity in  $\alpha_1$  adrenoceptors has been widely documented by gene cloning technologies and three different subtypes have been cloned, according to the indications of the International Union of Pharmacology, pharmacologically characterized and named  $\alpha_{1A}$ ,  $\alpha_{1B}$ , and  $\alpha_{1D}$  [21]. The distribution of these  $\alpha_1$  adrenoceptors in human ureter was studied using quantitative real-time PCR and  $\alpha_1$  adrenoceptors was found that each ureteral region was endowed with mRNA encoding  $\alpha_1$  adrenoceptors subtypes, although with differences in terms of the amount expressed and receptor distribution [21]. The  $\alpha_{1A}$  subtype accounted for about 38% of total adrenoceptors [22]. The  $\alpha_{1D}$  subtype mRNA was highly expressed in each ureteral region, accounting for about 54% of total adrenoceptors mRNA [22]. The  $\alpha_{1B}$  subtype accounted for about 8% [21]. In the proximal and middle ureter, the distribution of adrenoceptors was  $\alpha_{1D} \geq \alpha_{1A} > \alpha_{1B}$ , like that of the total ureter [22]. The  $\alpha_{1D}$  subtype expression was significantly higher than the  $\alpha_{1A}$  subtype expression. In the distal ureter, the distribution of adrenoceptors was  $\alpha_{1D} > \alpha_{1A} > \alpha_{1B}$  [22]. The distal ureter expressed the highest amount of

$\alpha_1$  Adrenoceptors subtype [22]. Alpha<sub>1A</sub>-adrenoceptors that is primarily located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Silodosin is a highly selective for these receptors. Blockade of these alpha<sub>1A</sub>-adrenoceptors causes smooth muscle in these tissues to relax [23]. Silodosin has been demonstrated in vitro that the alpha<sub>1A</sub>: alpha<sub>1B</sub> binding ratio of silodosin is (162:1) which is extremely high [24]. It has a substantially lower affinity for alpha<sub>1B</sub>-adrenoceptors that are primarily located in cardiovascular system [23]. Tamsulosin exhibits selectivity for both alpha<sub>1A</sub> and alpha<sub>1D</sub> receptors over the alpha<sub>1B</sub> adrenoceptor subtype [26]. These three AR subtypes have a distinct distribution pattern in human tissue [22]. Tamsulosin hydrochloride is an alpha<sub>1</sub> adrenoceptor (AR) blocking agent used for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) [25]. Whereas approximately 70% of the alpha<sub>1</sub>-receptors in human prostate are of the alpha<sub>1A</sub> subtype, the human bladder contains predominantly the alpha<sub>1D</sub> subtype while blood vessels express predominantly alpha<sub>1B</sub> subtype [27].

#### Patients and Methods

A prospective and randomized controlled study was conducted in the department of Urology, National Institute of Kidney Diseases & Urology (NIKDU), Dhaka, Bangladesh. Starting from October 2018, till September 2019; a total of 96 patients (F=56; M=40) who were in the age group (17–60) years, and had non-impacted, unilateral, uncomplicated lower or middle ureteral stones which were  $\leq 0.9$ cm, were enrolled in a prospective study and they were randomized into two groups. Group 1 received tamsulosin (0.4mg), and group 2 received silodosin (8mg) for a maximum period of 4 weeks. The patients were followed up weekly or biweekly with imaging studies.

#### The Study Exclusion criteria

1. Diabetes Mellitus.
2. Urinary tract infection.
3. Severe hydronephrosis.
4. Hypotension.
5. Ureteral strictures.
6. Multiple stones.
7. Solitary kidney.
8. Current use of any type of alpha-blocker.
9. Asthma and gastrointestinal ulcers.
10. Stones larger than 10 mm in greatest dimension.

The sample size of the study was arbitrarily determined. The patients were diagnosed by unenhanced computed tomography (CT) scans and re-evaluated with ultrasonography, plain X-ray and unenhanced (CT) scans whenever they were necessary. The stone size was calculated on the CT scan by using a digital ruler and the greatest dimension of the stone was taken into consideration as the stone size.

All the patients provided informed written consents and they were properly informed about the study in which they would be enrolled. The patients were randomly allocated into two treatment groups of 48 patients each. The patient demographics in the two groups, in terms of the size of the stones in the two groups, their locations in terms of the laterality and their locations in the ureter. Group A received tamsulosin (0.4 mg) daily, whereas Group B received silodosin (8mg) daily, for a maximum period of 6 weeks. All the patients were prescribed the 50 mg diclofenac tablet on demand for pain relief. The patients were advised that on experiencing an episode of unbearable ureteric colic, they should immediately report to us. The patients were followed up weekly or 3 times weekly with X-rays of the abdomen and the pelvis and ultrasonography. The patients were instructed to record the time and date of the stone passage. The follow up continued until the stone spontaneously passed, as reported by the patient, or for a maximum period of 6 weeks. The primary endpoint was the stone expulsion rate and the secondary endpoints were the stone expulsion time. The stone expulsion rate was defined as the percentage of patients that spontaneously pass their stones within the follow up period (i.e.6 weeks), whereas the stone expulsion time was defined as the number of days from the random allocation to the stone expulsion.

#### DATA ANALYSIS


The statistical analysis was performed by using the Student's t-test to compare continuous variables between the two groups, and the Chi-square test was used for categorical variables. A p value of  $< 0.05$  was considered to be statistically significant.

#### RESULTS

Four patients in Group A and six patients in Group B were lost to follow-up, with 86 patients remaining for per-protocol analyses. No significant differences were found between the groups with respect to age, stone size, or stone location (Table 1). Spontaneous stone expulsion was observed in 26 of 44 patients (59%) in Group A and in 34 of 42 patients (80%) in Group B (P=0.027). The stone expulsion rate

was significantly higher in Group B than in Group A. There was also a significant difference between the


groups with regards to the mean stone expulsion time ( $p= 0.01$ ).



**Fig-1: Sex distribution of patients**

**Table-1: Demographic data of the two study groups**

NO. of patients	Group A (n=44) (Tamsulosin)	Group B (n=42) (Silodosin)	P value
Sex:			0.47
Male	25	27	
Female	19	15	
Mean age± SD(years)	37±11	35±10	0.22
Mean stone Size±SD (mm)	6.9±1.9	7.0±2.1	0.51
Stone location:			0.49
Left	23	25	
Right	21	17	
Stone position:			0.19
Lower ureter	18	23	
Mid ureter	26	19	
None of the differences are statistically significant.			



**Fig-2: Stone location**

**Table-2: Results according to treatment**

Endpoint	Group A (n=44) (Tamsulosin)	Group B (n=42) (Silodosin)	P value
Primary end point: Stone expulsion rate	26/44 (59%)	34/42 (80%)	0.027
Secondary end point: Time to stone expulsion (days).	19.5±7.5	12.5± 3.5	0.01
Both differences are statistically significant			

The mean expulsion time was  $19.5 \pm 7.5$  days in Group A vs.  $12.5 \pm 3.5$  days in Group B (Table 2). In table (1) we notice that despite the random allocation of the patients into the two treatment groups, the difference in stone size, stone location, sex of the patients and laterality was not significant; meaning that the difference in these variables is negligible, and there was no bias in patients' randomization.

## DISCUSSION

Ureteral colic, which is mainly due to stones, represents 1 to 2% of the emergency room admissions [28]. With the introduction of effective medical therapeutic agents in the market, there has been a significant improvement in the medical management of the ureteral calculi [5, 8, 12]. Several studies findings indicate that alpha blockers facilitate ureteral stone passage while nifedipine may provide a marginal benefit [6]. These have demonstrated that this approach may facilitate and accelerate the spontaneous passage of ureteral stones [2, 5, 15]. Similar findings have been reported by Hollingsworth and associates, who recently performed a meta-analysis of studies involving alpha blockers or nifedipine in patients with ureteral stones [29]. The likelihood of a ureteral stone passage is dependent on several factors, which include the stone size and the location and the ureteral conditions [12-14]. Ibrahim AI *et al.* has demonstrated that stone passage rates between 71–98% for the distal ureteral stones which are less than 5 mm and from 25–53% for those which are between 5 and 10 mm [30]. The role of adrenergic receptors in the human ureter was first described in 1970 [31]. It was shown later, that the alpha-adrenergic receptors were classified into three different subtypes of  $\alpha_{1A}$ ,  $\alpha_{1B}$  and  $\alpha_{1D}$ , of which the distribution in the human ureter was  $\alpha_{1D} > \alpha_{1A} > \alpha_{1B}$  [22]. It was also shown that the alpha-adrenergic receptor agonists had a stimulatory effect on the ureteral smooth muscle, whereas the beta-adrenergic receptor agonists had an inhibitory effect [32]. The alpha-adrenergic receptor agonists prevent the uncoordinated muscle activity which is seen in renal colic, while maintaining ureteral peristalsis, which might facilitate a spontaneous stone passage [33]. The alpha blockers mainly produce relaxation of the distal human ureter by reducing the ureteric smooth muscle tone rather than completely ablating its activity [33]. Two meta-analyses provided a high level of evidence for the clinical benefit of the alpha blockers in the patients with distal ureteral calculi, in which the patients who were given alpha blockers had 52% and 44% greater likelihoods of stone passage than those who were not given such treatment [29, 34]. The treatment effect on the expulsion rate was

partially lost, as the sizes of the stones decreased, because of the high spontaneous expulsion rate of the small stones (4). By way of example only, De Sio *et al.*, Wang *et al.*, and Yilmaz *et al.* reported better stone expulsion rates (81%, 79%, AND 90%, respectively) in patients who received 0.4 mg tamsulosin daily than in controls (54%, 53%, AND 58%, respectively) [35-37]. Although most of the studies used tamsulosin, which is a selective  $\alpha_{1A}/\alpha_{1D}$  adrenergic receptor antagonist, the efficacies of the other alpha blockers such as doxazosin, terazosin, alfuzosin and naftopidil were also indicated [36, 38, 39]. Wang *et al.*, Yilmaz *et al.*, and Agrawal *et al.* demonstrated the efficacy of  $\alpha_1$ -adrenoceptor antagonists in the management of lower ureteral stones regardless of the type of alpha-blocker used [36, 37, 40]. Many studies have been published on  $\alpha_1$ -adrenoceptors in the human ureter since the first report in 1970; Malin *et al.* first described the presence of  $\alpha$ - and  $\beta$ -adrenoceptors through the entire length of the human ureter and the physiological response (increased tone and frequency of contractions) of the ureter when exposed to  $\alpha$  adrenoceptor agonists [31]. In 2005, Sigala *et al.* found that  $\alpha_{1D}$ - and  $\alpha_{1A}$ -adrenoceptors were expressed in significantly larger amounts than  $\alpha_{1B}$ -adrenoceptors in the human ureter, and these authors also demonstrated that the distal ureter expressed a greater amount of  $\alpha_1$ -adrenoceptor mRNA than the proximal and middle ureter [41]. Itoh *et al.* reported that  $\alpha_{1D}$ -adrenoceptor mRNA is more highly expressed than  $\alpha_{1A}$ -adrenoceptor mRNA in each region of the ureter [33]. According to their results, a  $\alpha_{1D}$ -adrenoceptor blocker can be expected to be more effective for the expulsion of ureteral stones than a  $\alpha_{1A}$ -adrenoceptor blocker [22, 41]. However, Tomiyama *et al.* reported that, in the hamster ureter, ureteral contraction was mediated mainly by  $\alpha_{1A}$ -adrenoceptors, even though  $\alpha_1$  adrenoceptors were more prevalent [42]. Recently, it was found that  $\alpha_{1A}$  adrenoceptors is the main participant in phenylephrine-induced ureteral contraction in the human isolated ureter [43]. Our results indicate that a  $\alpha_{1A}$ -adrenoceptor blocker is more effective than a  $\alpha_{1D}$ -adrenoceptor blocker with respect to stone expulsion rate and the time to stone expulsion suggesting more clinical usefulness of  $\alpha_{1A}$ -adrenoceptor blockers. Silodosin was approved for BPH by the US Food and Drug Administration in October 2008 [44]. Silodosin is a highly selective  $\alpha_{1A}$ -adrenoceptor antagonist, which has 56-fold affinity for  $\alpha_{1A}$ -over  $\alpha_{1D}$ -adrenoceptors [33]. Our study has compared the efficacy between tamsulosin and silodosin and our results are also very encouraging with stone expulsion rate of (80%) in group B who received silodosin (8mg) compared to (59%) of group A who received tamsulosin

(0.4 mg) which was a significant difference (P value=0.027). Regarding the incidence of the retrograde ejaculation, which is the most common side effect of silodosin (which has been stated to be very common among other side effects) [45-49], there has been a consensus among many urologists, that its occurrence should be considered as a sign of the efficacy, rather than an adverse effect of the treatment [45]. Silodosin appears to relax the smooth muscles of the genital tract and the lower urinary tract enough to induce a retrograde ejaculation [46]. This was reflected in the finding that the patients who had the greatest relief from the lower urinary tract symptoms had a higher likelihood of the retrograde ejaculation [46]. This observation suggests that the retrograde ejaculation is actually an indirect indicator of the relaxation of the smooth musculature that induced by silodosin [48]. The advantage of the medical expulsive therapy is important, because the risks which are related to a surgical intervention are not trivial [50]. Studies have reported the overall complication rates after ureteroscopic lithotripsies to be 11–22%, with major complications such as ureteral perforations, avulsions and strictures occurring during 4–6% of the procedures [50]. Urinomas and sub capsular bleeds have been reported in 16–33% of the patients who are treated with shock wave lithotripsy (ESWL) [51]. Therefore the medical expulsive therapy should be offered as a cost-effective treatment for the patients with distal ureteral calculi, who are amenable to a waiting management. Limitations encountered during study were: (1) Relatively small sample size, and (2) The cost of silodosin was much higher than any available alpha blocker.

## CONCLUSIONS

From this study we identified that: (1). Silodosin (as an example of a selective  $\alpha_{1A}$ -adrenoceptor antagonist) was more effective than tamsulosin (as an example of a  $\alpha_{1D}$  and  $\alpha_{1A}$ -adrenoceptor antagonist) with respect to stone expulsion rate for ureteral stones and the time to stone expulsion, despite the abundance of  $\alpha_{1D}$ -adrenoceptors in human ureter. (2). A conservative approach should be considered as an option in the management of the uncomplicated, small, distal ureteral calculi.

## RECOMMENDATIONS

We recommend the use of silodosin in the medical expulsive therapy for ureteric stones, since it is clinically superior to tamsulosin in this type of therapy. Further studies on medical expulsive therapy for ureteric stones, are required to determine the superiority

of  $\alpha_{1A}$  adrenoceptor antagonist (silodosin) versus  $\alpha_{1D}/\alpha_{1A}$  adrenoceptor antagonist (tamsulosin). These studies should include larger sample size.

## REFERENCES

1. Shah, J., & Whitfield, H. N. (2002). Urolithiasis through the ages. *BJU international*, 89(8), 801-810.
2. Resim, S., Ekerbicer, H., & Ciftci, A. (2005). Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. *International journal of urology*, 12(7), 615-620.
3. Phillips, E., Kieley, S., Johnson, E. B., & Monga, M. (2009). Emergency room management of ureteral calculi: current practices. *Journal of endourology*, 23(6), 1021-1024.
4. Seitz, C., Liatsikos, E., Porpiglia, F., Tiselius, H. G., & Zwergel, U. (2009). Medical therapy to facilitate the passage of stones: what is the evidence?. *European urology*, 56(3), 455-471.
5. Porpiglia, F., Ghignone, G., Fiori, C., Fontana, D., & Scarpa, R. M. (2004). Nifedipine versus tamsulosin for the management of lower ureteral stones. *The Journal of urology*, 172(2), 568-571.
6. Preminger, G. M. (2007). American Urological Association Education and Research, Inc; European Association of Urology. *Eur. Urol.*, 52, 1610-1631.
7. Miller, O. F., & KANE, C. J. (1999). Time to stone passage for observed ureteral calculi: a guide for patient education. *The Journal of urology*, 162(3 Part 1), 688-691.
8. Liatsikos, E. N., Katsakiori, P. F., Assimakopoulos, K., Voudoukis, T., Kallidonis, P., Constantinides, C., & Perimenis, P. (2007). Doxazosin for the management of distal-ureteral stones. *Journal of endourology*, 21(5), 538-541.
9. "Drugs.com. (2008). Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia". Retrieved, 02-13.
10. Ferre, R. M., Wasielewski, J. N., Strout, T. D., & Perron, A. D. (2009). Tamsulosin for ureteral stones in the emergency department: a randomized, controlled trial. *Annals of emergency medicine*, 54(3), 432-439.
11. Hermanns, T., Sauermann, P., Rufibach, K., Frauenfelder, T., Sulser, T., & Strebel, R. T. (2009). Is there a role for tamsulosin in the treatment of distal ureteral stones of 7 mm or less? Results of a randomised, double-blind, placebo-controlled trial. *European urology*, 56(3), 407-412.

12. Vincendeau, S., Bellissant, E., Houlgatte, A., Doré, B., Bruyère, F., Renault, A., & Guillé, F. (2010). Tamsulosin hydrochloride vs placebo for management of distal ureteral stones: a multicentric, randomized, double-blind trial. *Archives of internal medicine*, 170(22), 2021-2027.
13. Ochoa-Gómez, R., Prieto-Díaz-Chávez, E., Trujillo-Hernández, B., & Vásquez, C. (2011). Tamsulosin does not have greater efficacy than conventional treatment for distal ureteral stone expulsion in Mexican patients. *Urological research*, 39(6), 491-495.
14. Yencilek, F., Erturhan, S., Canguven, O., Koyuncu, H., Erol, B., & Sarica, K. (2010). Does tamsulosin change the management of proximally located ureteral stones?. *Urological research*, 38(3), 195-199.
15. Gravina, G. L., Costa, A. M., Ronchi, P., Galatioto, G. P., Angelucci, A., Castellani, D., & Vicentini, C. (2005). Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. *Urology*, 66(1), 24-28.
16. Naja, V., Agarwal, M. M., Mandal, A. K., Singh, S. K., Mavuduru, R., Kumar, S., ... & Gupta, N. (2008). Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. *Urology*, 72(5), 1006-1011.
17. Bhagat, S. K., Chacko, N. K., Kekre, N. S., Gopalakrishnan, G., Antonisamy, B., & Devasia, A. (2007). Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi?. *The Journal of urology*, 177(6), 2185-2188.
18. John, T. T., & Razdan, S. (2010). Adjunctive tamsulosin improves stone free rate after ureteroscopic lithotripsy of large renal and ureteric calculi: a prospective randomized study. *Urology*, 75(5), 1040-1042.
19. Wen, C. C., & Nakada, S. Y. (2007). Treatment selection and outcomes: renal calculi. *Urologic Clinics of North America*, 34(3), 409-419.
20. McCune, D. F., Edelman, S. E., Olges, J. R., Post, G. R., Waldrop, B. A., Waugh, D. J., ... & Piascik, M. T. (2000). Regulation of the cellular localization and signaling properties of the  $\alpha 1B$ - and  $\alpha 1D$ -adrenoceptors by agonists and inverse agonists. *Molecular pharmacology*, 57(4), 659-666.
21. Hieble, J.P., Bylund, D.B., Clarke, D.E. (1995). International union of pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. *Pharmacol. Rev.* 47: 267
22. Itoh, Y., Kojima, Y., Yasui, T., Okada, A., Tozawa, K., Kohri, K. (2007). Examination of alpha 1 adrenoceptor subtypes in the human ureter. *Int. J. Urol*, 14: 749-53.
23. Kawabe, K., Yoshida, M., Homma, Y., & Silodosin Clinical Study Group. (2006). Silodosin, a new  $\alpha 1A$ -adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. *BJU international*, 98(5), 1019-1024.
24. Anon. (2004). KMD 3213: KAD 3213, Silodosin. *Drugs RD*, 5:50-1.
25. Eri, L.M., Tveter, K.J. (1995). A-blockade in the treatment of symptomatic benign prostatic hyperplasia. *J Urol*, 154:923-34.
26. Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A. F. G. V. M., & Abrams, P. (1996). Tamsulosin, the First Prostate-Selective  $\alpha$  (1A)-Adrenoceptor Antagonist. *European urology*, 29, 155-167.
27. Faure, C., Pimoule, C., Vallancien, G., Langer, S. Z., & Graham, D. (1994). Identification of  $\alpha 1$ -adrenoceptor subtypes present in the human prostate. *Life sciences*, 54(21), 1595-1605.
28. Galvin, D. J., & Pearle, M. S. (2006). The contemporary management of renal and ureteric calculi. *BJU international*, 98(6), 1283-1288.
29. Hollingsworth, J. M., Rogers, M. A., Kaufman, S. R., Bradford, T. J., Saint, S., Wei, J. T., & Hollenbeck, B. K. (2006). Medical therapy to facilitate urinary stone passage: a meta-analysis. *The Lancet*, 368(9542), 1171-1179.
30. Ibrahim, A. I. A., Shetty, S. D., Awad, R. M., & Patel, K. P. (1991). Prognostic factors in the conservative treatment of ureteric stones. *British journal of urology*, 67(4), 358-361.
31. MALIN Jr, J. M., DEANE, R. F., & Boyarsky, S. (1970). Characterisation of adrenergic receptors in human ureter 1. *British journal of urology*, 42(2), 171-174.
32. Weiss, R. M., Bassett, A. L., & Hoffman, B. F. (1978). Adrenergic innervation of the ureter. *Investigative urology*, 16(2), 123-127.
33. Tzortzis, V., Mamoulakis, C., Rioja, J., Gravas, S., Michel, M. C., & de la Rosette, J. J. (2009). Medical expulsive therapy for distal ureteral stones. *Drugs*, 69(6), 677-692.
34. Parsons, J.K., Hergan, L.A., Sakamoto, K., Lakin, C. (2007). Efficacy of alpha-blockers for the treatment of ureteral stones. *J. Urol*, 177: 983-87.
35. De Sio, M., Autorino, R., Di, Lorenzo, G. (2006). Medical expulsive treatment of distal ureteral

- stones using tamsulosin: a single-center experience. *J. Endourol*, 20: 12–16.
36. Wang, C.J., Huang, S.W., Chang, C.H. (2008). Efficacy of an alpha 1 blocker in expulsive therapy of lower ureteral stones. *J. Endourol*, 22: 41–6.
37. Yilmaz, E., Batislam, E., Basar, M.M., Tuglu, D., Ferhat, M., Basar, H. (2005). The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. *J. Urol*, 173: 2010–12.
38. Pedro, R.N., Hinck, B., Hendlin, K., Feia, K., Canales, B.K., Monga, M. (2008). Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. *J. Urol*, 179: 2244–47.
39. Sun, X., He, L., Ge, W., Lv, J. (2009). Efficacy of selective alpha1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones. *J. Urol*, 181: 1716–20.
40. Agrawal, M., Gupta, M., Gupta, A., Agrawal, A., Sarkar, A., Lavania, P. (2009). Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. *Urology*, 73: 706–9.
41. Sigala, S., Dellabella, M., Milanese, G. (2005). Evidence for the presence of alpha 1 adrenoceptor subtypes in the human ureter. *Neurourol. Urodyn*, 24: 142–8.
42. Tomiyama, Y., Kobayashi, K., Tadachi, M. (2007). Expressions and mechanical functions of alpha 1 adrenoceptor subtypes in hamster ureter. *Eur. J. Pharmco*, 573: 201–5.
43. Sasaki, S., Tomiyama, Y., Kobayashi, S., Kojima, Y., Kubota, Y., Kohri, K. (2011). Characterization of  $\alpha$  (1)-adrenoceptor subtypes mediating contraction in human isolated ureters. *Urology*, 77: 762 e13–17.
44. Cantrell, M.A., Bream-Rouwenhorst, H.R., Steffensmeier, A. (2008). Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. *Ann Pharmacother*, 42:558–63.
45. Kobayashi, K., Masumori, N., Kato, R. (2009). Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration. *Int J Impot Res*, 21:306–10
46. Kobayashi, K., Masumori, N., Hisasue, S. (2008). Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. *J Sex Med*, 5:2185–90.
47. Morganroth, J., Lepor, H., Hill, L.A., Volinn, W., Hoel, G. (2010). Effects of the selective alpha (1A)-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. *ClinPharmacol Ther*, 87: 609–13.
48. Tatemichi, S., Kiguchi, S., Kobayashi, M., Yamazaki, Y., Shibata, N., Uruno, T. (2006). Cardiovascular effects of the selective alpha1A-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. *Arzneimittelforschung*, 56:682–7.
49. Guimaraes, S., Moura, D. (2001). Vascular adrenoceptors: an update. *Pharmacol Rev*, 53:319–56.
50. Picozzi, S.C., Ricci, C., Gaeta, M. (2012). Urgent ureteroscopy as first-line treatment for ureteral stones: a meta-analysis of 681 patients. *Urol Res*, 40(5):581–6.
51. Lotan, Y., Gettman, M.T., Roehrborn, C.G., Caddeu, J.A., & Pearle, M.S. (2002). Management of ureteral calculi: a cost comparison and decision making analysis. *J. Urol*, 167:1621–29.

---

**Cite This Article:** Khan Nazrul Islam *et al* (2021). Comparison of Silodosin (8 Mg) Versus Tamsulosin (0.4Mg), Both in Terms of the Stone Expulsion Rate and the Time to Stone Expulsion. *East African Scholars J Med Sci*, 4(2), 50-57.